AKR1B1 Polyclonal Antibody

AKR1B1 Polyclonal Antibody

The AKR1B1 Polyclonal Antibody is a highly specific and sensitive tool designed for the detection and quantification of AKR1B1 protein in various biological samples. This antibody has been meticulously developed and rigorously validated to ensure optimal performance and reliability in a wide range of applications, including Western blotting, immunohistochemistry, and enzyme-linked immunosorbent assays (ELISA).

AKR1B1, also known as aldose reductase, is a key enzyme involved in the metabolism of glucose and the detoxification of reactive aldehydes. Dysregulation of AKR1B1 has been implicated in various diseases, including diabetic complications, cancer, and neurodegenerative disorders. Therefore, accurate measurement of AKR1B1 protein levels is crucial for understanding its role in disease pathogenesis and for the development of targeted therapeutic interventions.

The AKR1B1 Polyclonal Antibody exhibits exceptional specificity, recognizing only the target protein without cross-reactivity to other closely related proteins. This high specificity ensures reliable and accurate results, minimizing the risk of false positives or false negatives. Additionally, this antibody demonstrates excellent sensitivity, enabling the detection of low levels of AKR1B1 protein even in samples with limited abundance.

Furthermore, the AKR1B1 Polyclonal Antibody has been extensively validated using various experimental approaches, including siRNA knockdown, overexpression, and immunofluorescence staining. These validation studies have confirmed the antibody's ability to specifically detect AKR1B1 protein and its suitability for use in diverse experimental settings.

In summary, the AKR1B1 Polyclonal Antibody is a valuable tool for researchers and clinicians studying AKR1B1 protein expression and its implications in various diseases. With its exceptional specificity, sensitivity, and rigorous validation, this antibody offers reliable and accurate results, facilitating further understanding of AKR1B1's role in disease pathogenesis and aiding in the development of targeted therapeutic strategies.